A 2-year-old child with moderate mitral stenosis secondary to rheumatic heart disease presents with dyspnea on exertion and recurrent respiratory tract infections. Echocardiography confirms a mitral valve area of 1.2 cm². Medical management is initiated to reduce symptoms and prevent complications. Which drug is the preferred first-line agent for rate control and symptom relief in this patient?